Over the past few days, the news from GoodRx Holdings (NASDAQ: GDRX) hasn't been all that good. On Thursday the online ...

GoodRx (NASDAQ:GDRX – Get Free Report) had its price target lowered by Barclays from $10.00 to $6.00 in a research note ...

Welcome to the GoodRx third-quarter 2024 earnings call. As a reminder, today's conference call is being recorded. I would now ...

Three independent pharmacies have filed lawsuits accusing GoodRx, which markets a prescription drug discount card, of ...

Barclays lowered the firm’s price target on GoodRx (GDRX) to $6 from $10 and keeps an Overweight rating on the shares post the Q3 report.

GoodRx has been hit with a series of antitrust class actions in California and Rhode Island federal courts challenging the ...

In a report released today, Jailendra Singh from Truist Financial maintained a Hold rating on GoodRx Holdings (GDRX – Research Report), ...

Drug coupon aggregator GoodRx and pharmacy benefit managers including CVS Caremark and Express Scripts have been hit with at least three class action lawsuits accusing them of working together to ...

Novo Nordisk disclosed it knows of 10 deaths and 100 hospitalizations from people taking compounded copies of its weight loss ...

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 59%. Looking ahead, revenue ...

GoodRx Holdings Inc (GDRX) reports robust growth in adjusted EBITDA and Pharma Manufacturer Solutions revenue, despite facing ...

The usual PBM strategy cuts an independent pharmacy's share of the prescription revenue to just 3 cents per pill dispensed, ...